Pharmacovigilance Requirements for Natural Health Products in the European Union: What Canadian Manufacturers Need to Know

The European Union(EU) is the world's second-largest pharmaceutical market, with the herbal medicines segment alone projected to reach USD 89 billion by 2029.

For Canadian manufacturers of Natural Health Products (NHPs), expansion into the European Union can be commercially attractive, but it is rarely straightforward from a regulatory standpoint. The challenge is not simply one of product registration. It is one of classification, governance, post-market accountability, and readiness to operate within one of the world’s most mature pharmacovigilance frameworks.

Under EU law, the products marketed in Canada as NHPs will, in most cases, be classified and regulated as Herbal Medicinal Products (HMPs), a sub-category of medicinal products subject to the full machinery of European pharmaceutical regulation

Once a herbal product is placed on the EU market under a medicinal framework, the expectation is clear: the company must operate a structured, inspectable, and continuously functioning pharmacovigilance system.

The good news is that Canadian companies are not starting from zero. In fact, many of the underlying safety principles that support Health Canada compliance also support EU readiness.

The EU Regulatory Framework for Herbal Medicinal Products

Herbal medicinal products are governed by the EU's pharmaceutical legislation, the Community Code on medicinal products and supplemented by the "Herbal Directive," which created a simplified registration route for products with a long history of traditional use. The European Medicines Agency's Committee on Herbal Medicinal Products (HMPC) underpins the system by publishing EU herbal monographs and maintaining the EU list of herbal substances, preparations, and combinations. Where an HMPC monograph covers your indication and posology, you may reference it directly, materially reducing the evidence burden of an application.

Three pathways to market

European law offers three principal routes, each with a different evidentiary threshold:

• Full Marketing Authorisation demands a complete dossier with pre-clinical and clinical data establishing quality, safety, and efficacy. It carries the broadest permitted claims but the highest evidentiary bar, and it triggers the most extensive pharmacovigilance obligations.

• Well-Established Use (WEU) Marketing Authorisation permits reliance on published scientific literature in place of new clinical trials, provided the herbal substance has at least ten years of medicinal use within the EU, with recognized efficacy and an acceptable safety profile.

• Traditional-Use Registration (TUR) is the pathway most analogous to Canada's product-licence (NPN) process and the most pragmatic entry route for the majority of Canadian NHP manufacturers. It applies to oral, external, or inhalation preparations with a minimum of 30 years of traditional medicinal use, of which at least 15 must be within the EU/EEA. The bar for proving safety and efficacy is lower, but a full quality dossier remains mandatory — and, critically, the full pharmacovigilance obligations of EU law apply to TUR holders.

The Legal Architecture of EU Pharmacovigilance

A Canadian company entering Europe assumes legal responsibility for the ongoing safety surveillance of its products throughout their life on the market.

The framework that governs this is layered, but its logic is coherent: primary EU pharmaceutical legislation sets the obligations; a landmark 2010 reform strengthened the system, created the Pharmacovigilance Risk Assessment Committee (PRAC), and made EudraVigilance, the EU's centralised adverse-reaction database, the mandatory electronic reporting route; and the European Medicines Agency's Good Pharmacovigilance Practices (GVP) guidelines translate the law into detailed operational practice across the full safety lifecycle, from signal detection through benefit-risk evaluation to communication with regulators and the public.

The consequences of non-compliance are not theoretical. National competent authorities and the EMA can impose urgent safety restrictions, trigger reviews that result in EU-wide label changes or suspensions, and revoke registrations on safety grounds. Most Member States provide for substantial financial penalties under national law. In Europe, the safety system is not adjacent to your market access. It is your market access.

Governance: The QPPV and the PSMF

Canadian manufacturers with solid domestic compliance programs usually have a useful foundation: complaint handling, serious adverse reaction reporting, internal procedures, and quality oversight. These are important strengths. But they do not, on their own, meet EU expectations.

The most visible structural gap is governance.

Under the EU model, companies placing medicinal products on the market are expected to appoint a Qualified Person Responsible for Pharmacovigilance (QPPV) based in the EU or EEA. This is a central regulatory function with oversight responsibility for the pharmacovigilance system as a whole. The QPPV must be continuously available, appropriately qualified, and capable of interacting with authorities on safety matters.

For Canadian companies entering Europe without an established local presence, this requirement is often the first practical hurdle. A domestic safety lead in Canada cannot simply be relabeled for European purposes.

Equally important is the Pharmacovigilance System Master File (PSMF). This document is not just a procedural summary. It is the regulator’s window into how the company’s pharmacovigilance system is designed, governed, documented, and controlled. An incomplete or outdated PSMF is more than poor documentation; it signals weak system stewardship and invites regulatory concern.

Experienced inspectors tend to look for consistency between what the PSMF says and what the organization actually does.

Reporting Requirements

The EU adverse reaction reporting framework is one of the clearest examples of where Canadian and European expectations diverge in practice.

Canadian companies are generally familiar with the logic of serious adverse reaction reporting. That logic still applies in Europe. However, the EU system extends further, particularly in the handling of non-serious reports, electronic reporting obligations, and the infrastructure needed to support centralized submission.

Reportability matrix

All Individual Case Safety Reports (ICSRs) must be submitted electronically to EudraVigilance in the internationally standardized electronic format, via the EMA's submission gateway. Paper and email submissions are not acceptable for marketed products. Reportability turns on three variables — seriousness, expectedness, and geography — with expectedness assessed against the product's approved information at the time the reaction is reported.

EU adverse reaction reporting criteria for HMP holders.

Type of Adverse Reaction	EEA — expedited?	Non-EEA — expedited?	Non-serious EEA (90 days)?
Serious, expected	Yes — 15 days	No	—
Serious, unexpected	Yes — 15 days	Yes — 15 days	—
Non-serious, expected	No	No	Yes — 90 days
Non-serious, unexpected	No	No	Yes — 90 days

In some organizations, pharmacovigilance is treated as a reporting obligation: receive the complaint, assess the case, submit when necessary, and archive the file. The EU approach is broader and more proactive. Authorities expect companies to monitor cumulative data, identify patterns, assess new risks, and demonstrate that safety decisions are grounded in an active surveillance process.

Periodic Reporting and Literature Surveillance

Periodic Safety Update Reports (PSURs): Full marketing-authorisation holders submit PSURs at intervals set by an EU reference list, through a centralised repository. TUR holders are generally exempt from routine PSUR submission unless an authority imposes one as a condition of registration — a meaningful contrast with Canada's Annual Summary Report obligation, which applies to all NHP licensees. Even where exempt, however, every TUR holder must maintain an internal periodic safety assessment: a rolling review of cumulative safety data supporting signal detection and benefit-risk evaluation.

Literature surveillance: Systematic literature monitoring is mandatory, documented, and risk-based. For herbal products, it must cover not only the finished product but the herbal substance and its preparations. A defensible programme defines its databases, search terms, and frequency; documents screening and triage; and links identified cases to the reporting and signal workflows.

The European market remains highly attractive for herbal and natural product manufacturers, but success depends on entering with the right assumptions. The key question is no longer whether a Canadian company can register a product in Europe. Many can, with the right pharmacovigilance strategy that begins with rigorously aligning with Canadian requirements. The more important question is whether the company is prepared to operate at the level of pharmacovigilance oversight Europe expects once that product is approved. That is where competitive advantage now lies.

For companies willing to approach EU expansion with seriousness, discipline, and forward-looking pharmacovigilance design, the opportunity is very real. And for those already operating strong systems in Canada, the path forward is more attainable than it first appears.

The objective is not to start over. It is to build intelligently on what already exists—and elevate it to a standard that can withstand both inspection and growth.

How VigiQuest Analytics Can Help

Whether you are scaling up from a startup with a single product or running a multinational with a complex portfolio targeting the European Market, VigiQuest Analytics can assess your current pharmacovigilance posture and recommend the right path forward. Our pharmacovigilance and regulatory affairs practice supports NHP licensees with:

•  Compliance gap analyses and GVP inspection readiness assessments

• SOP development, Safety Data Exchange Agreement review, and PV staff training

• End-to-end adverse reaction case management and Annual Summary Report preparation

• Signal detection, benefit-risk evaluation, and Health Canada response support

• Strategic advice on the evolving NHP regulatory framework

 Schedule your free, no-obligation assessment today.